HomeCompareCNVVY vs DGRO

CNVVY vs DGRO: Dividend Comparison 2026

CNVVY yields 2.49% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNVVY wins by $171.58M in total portfolio value· pulled ahead in Year 2
10 years
CNVVY
CNVVY
● Live price
2.49%
Share price
$11.64
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$171.61M
Annual income
$159,331,380.90
Full CNVVY calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — CNVVY vs DGRO

📍 CNVVY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNVVYDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNVVY + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNVVY pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNVVY
Annual income on $10K today (after 15% tax)
$211.86/yr
After 10yr DRIP, annual income (after tax)
$135,431,673.77/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, CNVVY beats the other by $135,431,469.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNVVY + DGRO for your $10,000?

CNVVY: 50%DGRO: 50%
100% DGRO50/50100% CNVVY
Portfolio after 10yr
$85.82M
Annual income
$79,665,810.43/yr
Blended yield
92.83%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNVVY buys
0
DGRO buys
0
No recent congressional trades found for CNVVY or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNVVYDGRO
Forward yield2.49%2.13%
Annual dividend / share$0.29$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%0%
Portfolio after 10y$171.61M$31.6K
Annual income after 10y$159,331,380.90$239.96
Total dividends collected$170.67M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CNVVY vs DGRO ($10,000, DRIP)

YearCNVVY PortfolioCNVVY Income/yrDGRO PortfolioDGRO Income/yrGap
1$11,198$498.50$11,293$213.22$95.00DGRO
2← crossover$13,026$1,043.44$12,730$217.32+$296.00CNVVY
3$16,206$2,268.61$14,326$221.10+$1.9KCNVVY
4$22,616$5,275.73$16,098$224.56+$6.5KCNVVY
5$37,961$13,761.64$18,064$227.74+$19.9KCNVVY
6$83,794$43,175.04$20,246$230.65+$63.5KCNVVY
7$267,794$178,135.05$22,666$233.30+$245.1KCNVVY
8$1,350,649$1,064,109.17$25,349$235.73+$1.33MCNVVY
9$11,476,878$10,031,683.35$28,325$237.94+$11.45MCNVVY
10$171,611,640$159,331,380.90$31,624$239.96+$171.58MCNVVY

CNVVY vs DGRO: Complete Analysis 2026

CNVVYStock

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Full CNVVY Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this CNVVY vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNVVY vs SCHDCNVVY vs JEPICNVVY vs OCNVVY vs KOCNVVY vs MAINCNVVY vs VIGCNVVY vs NOBLCNVVY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.